Envigo announces new double knockout mouse model

By Melissa Fassbender contact

- Last updated on GMT

(Image: Envigo)
(Image: Envigo)

Related tags: Cancer

Envigo has launched a mixed-background mouse to support oncology, immuno-oncology, and infectious disease research.

The company launched the “R2G2” mouse at the American Association for Cancer Research (AACR) annual meeting​ this week in Washington, DC.

According to the Envigo, the R2G2, a Rag2/IL2RG double knockout model was developed by backcrossing the common gamma chain gene mutation (IL2RG) on to a unique C57BL/6 and 129 mixed background mouse with a mutation in the recombination activating gene 2 (Rag2).

R2G2 is a triple immunodeficient mouse model on a unique background,​” Mike Caulfield, President, North America Operations, Envigo, told Outsourcing-Pharma.com.

Due to being less radiosensitive, the R2G2 model allows researchers to use a broader range of radiation in their oncology research​,” he said.

Additionally, Caulfield explained that because the model is not “leaky” it can be used for longer term studies without interference from the formation of T and B cells.

The company is currently validating the model’s potential humanization benefits and expects to release results in early summer.

The new R2G2 model is part of Envigo’s model sampling program.

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related product

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q² Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Related suppliers

Follow us

Products

View more

Webinars